Research Study Summary
A randomised, double-blind, placebo-controlled, proof-of concept, dose-ranging study of BI 655066 in patients with active psoriatic arthritis.
Psoriatic arthritis is a chronic inflammatory disease which can affect any joint in your body. Psoriatic arthritis usually develops in people who have psoriasis, a disease in which scaly red and white patches develop on the skin. Both psoriasis and psoriatic arthritis are caused by an overactive immune system where healthy body tissue is attacked by mistake. This study will look at a new investigational drug, BI 655066, and provide proof-of-concept and dose-ranging data of BI 655066 in patients with active psoriatic arthritis.
To Learn more
CW ID: 216053
Date Last Changed:
June 14, 2016
Clinical Trial Snapshot
- Both Male and Female
- 18 and up
- Overall Status
- Boehringer Ingelheim
- 16 Weeks
- Facility Type
- Have psoriatic arthritis (PsA) symptoms for ≥ 6 months prior to screening
- Have PsA on the basis of the Classification Criteria for Psoriatic Arthritis (CASPAR) with peripheral symptoms
- Have ≥5 tender joints and ≥5 swollen joints at screening
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.